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Abstract 
 
Defects in the regulation of cellular replication are some of the primary causes of cancer in 
humans.  The E2F3 protein, a member of the E2F transcription factor family, acts to control 
progression past the G1/S-checkpoint during cellular replication.  One way that E2F3 is regulated is 
via phosphorylation.  The phosphorylated form of this protein is often found in tumor cell lines and 
is thought to be linked to cancer.  However, the exact pathways and interactions of this protein are 
not well characterized in vivo.  The purpose of this study is to better understand how E2F3 
phosphorylation controls the cell cycle in vivo and thus how it affects development as well as tumor 
incidence, growth, and metastases in mice. 
The retinoblastoma gene, which promotes pituitary and thyroid cancer when one copy is 
knocked out, was combined with E2F3 mutations mimicking either the phosphorylated 
(E2F3
S390D
) or non-phosphorylated (E2F3
S390A
) form of the protein.  We observed tumor 
incidence and size, as well as metastases to other organs in these mice at 11 months of age.  Our 
data shows that a lack of E2F3 phosphorylation increases thyroid cancer incidence in female mice.  
Interestingly, both phospho-mimicking and non-phosphorylatable mutants of E2F3 appear to 
decrease pituitary tumor size, but not incidence, compared with wild type E2F3. 
Developmentally, mice lacking the retinoblastoma gene typically die between the embryonic ages 
of 13.5 and 15.5 days.  We observed survival at E11.5 and E13.5 days in Rb-null mice combined 
with one of the aforementioned E2F3 mutations.   We show that embryos with the 
phospho-mimicking mutant of E2F3 have decreased viability compared to wild-type and 
non-phosphorylatable mutants at E11.5. 
Since phosphorylation is an alteration at the chemical level, understanding this pathway 
could lead to novel forms of chemotherapy that help fight cancer associated with E2F3. 
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Introduction 
 
This study aims to look at the effects of E2F3 phosphorylation in the complete or partial 
absence of a functional retinoblastoma gene product.  Retinoblastoma is a member of the 
Retinoblastoma protein family, which also includes the proteins p107 and p130.  These proteins, 
often referred to as pocket proteins, regulate the effects of E2F transcription factors by selectively 
binding them and regulating how they interact with target DNA
1  
(Figure 1). The Rb 
protein is regulated via phosphorylation
2-3  
in a cell-cycle dependent manner
4-7 
. This regulation 
 
occurs through the actions of cyclin dependent kinases (Cdk’s) and their associated cyclins8-10. 
During the transition from the G1  to the S phase of the cell cycle, Cdk’s phosphorylate the Rb 
protein, changing its conformation and thus preventing it from binding to the E2F transcription 
factors
1
. Since E2F proteins are involved in regulating cellular proliferation
11,12
, mutation or loss 
of Rb often leads to aberrant proliferation and cancer in the affected organism. 
This was first recognized in humans with mutations in Rb who were prone to cancer of the retina, 
known as retinoblastoma
3,13,14
. Defects in Rb can also manifest themselves in other tissue types. In 
mice, mutation or absence of Rb often manifests as cancer of the thyroid and the pituitary
15
. 
 
 
 
 
Figure 143. General Rb-E2F pathway whereby E2F activity is controlled by 
the phosphorylation state of Rb. 
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Developmentally, when both copies of Rb are non-functional, the mouse embryo dies 
around the embryonic age of 13.5 days
16
. This is thought to occur when E2F’s that are no longer 
constricted by Rb bind to and activate genes necessary for progression past the G1-S checkpoint. 
As this essentially nullifies the checkpoint, cells rapidly proliferate and cause developmental 
defects in the growing embryos.  Specifically, in embryos lacking Rb, trophoblast stem cells in the 
placenta become over-proliferative.  This overabundance of trophoblast cells disrupts the normal 
labyrinth structure of the placenta and severely disrupts the normal process of nutrient transport 
between the mother and the embryos
16
. 
Analysis of the effect of the E2F family has been somewhat difficult, primarily due to 
 
differences in function among the various family members, as well as differences in tissue- 
specific functions.  Currently there are 8 known E2F genes in the E2F family.  It is thought that 
E2F1, E2F2, and E2F3a act as activators
17
, with their expression levels peaking during the G1-S 
transition
18-21
. Conversely, E2F3b, E2F4, E2F5, E2F6, E2F7, and E2F8 are thought to act as 
 
repressors, allowing cells to exit the cell cycle and differentiate
17 
(Figure 2). 
 
 
Figure 217. Genetic loci of the E2F family members, including their 
functions as either activators or repressors of transcription, as well as 
functional domains of the protein. 
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The expression levels of E2F3b, 4, and 5 remain relatively constant during the cell cycle
22,23 
where 
they function to recruit Rb to E2F-target sequences and thus repress transcription at that site.  This, 
however, is an oversimplified view of the issue.  As mentioned earlier, the importance of the 
various E2F’s appears to depend on the tissue. A lack of E2F1 and E2F2, for example, appears to 
cause diabetes in mice
24
, showing a link between these specific E2F’s and proper pancreas 
function.  Furthermore, different members of the E2F family appear to have varying degrees of 
importance in certain biochemical processes and pathways.  For example the Myc gene, a well 
known proto-oncogene, is known to induce S-phase as well as apoptosis.  However, these effects 
are mitigated by specific members of the E2F family.  When cells are deleted for E2F2 or E2F3, 
Myc’s ability to induce S phase is hindered; however, when deleted for E2F1 or E2F4 there are no 
noticeable differences
25
. In a similar vein, Myc’s ability to induce apoptosis is 
reduced in cells deleted for E2F1, but not in cells deleted for E2F2 or E2F3
25
. Such differences 
 
are often due to very slight physical changes between the proteins, such as the presence of a 
specific marked-box domain present in E2F1, but not in E2F3, which gives E2F1 its prevalence in 
the apoptosis pathway
26
. It is also common for differences to be caused by tissue-specific 
upstream events that preferentially activate or repress certain members of the E2F family.  In 
some cases, the specific E2F family member is not important, but rather its position on the 
chromosome determines how that locus is regulated spatiotemporally and thus determines the 
observed phenotype.  For example, replacing exon 1a of E2F3 with exon 1b of E2F3 or the ORF 
of E2F1 suppresses phenotypes arising from loss of E2F3a
27
. This points to transcriptional 
regulation of the given E2F3 locus, and not the specific form of the protein, as the major 
contributor to the observed phenotype. 
This idea of specific functions within the subgroups of activators and repressors is 
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especially important for the process of proliferation itself and is one of the reasons why E2F3 is 
being focused on in this study.  Previous work has shown that among the known activators, E2F3 
appears to have a prominent role in regulating proliferation, more so than either E2F1 or E2F2 in 
some instances
28,29
. A lack of E2F3 causes high levels of embryonic lethality in some mouse 
strains
28,30,31
. However, a lack of either E2F1 or E2F2 does not seem to drastically affect 
 
development in mice.  This observation was also supported by studies using mouse embryo 
fibroblasts (MEF’s) in which deletion of E2F3 caused a marked decrease in proliferation, 
whereas deletion of either E2F1 or E2F2 showed a much milder decrease in proliferation
32
. 
Another interesting observation is that activating members of the E2F family can often 
 
behave as tumor suppressors by inducing apoptosis in cells that are over-proliferative
33-35
. As 
mentioned earlier, mice heterozygous for the deletion of Rb die during embryonic development. 
One consequence of the Rb deletion is the induction of apoptosis via p53-dependent and 
independent pathways
35,36
. Interestingly, deletion of E2F1 or E2F3 in Rb-null embryos 
suppresses this process of apoptosis
29
. This suggests that these activating E2F’s also have a role 
 
in promoting apoptosis.  Lastly, in mice heterozygous for the Rb deletion, loss of E2F3 causes a 
decrease in pituitary tumors
36
. It also causes an increase in medullary thyroid carcinomas with 
more aggressive metastases of these growths to other organs
36
. One possible reason for the 
opposing effects seen in these organs could be tissue-specific differences present in either 
proliferative or apoptotic pathways.  The natural levels and phosphorylation states of the various 
E2F’s likely differs between the thyroid and the pituitary, accounting for the different trends 
observed. 
This particular project was founded on a few key ideas collected from various sources in 
the literature.  The first observation came from analyzing the E2F1 protein and how it interacts 
 6 
with Rb.  First, a number of potential phosphorylation sites were identified.  Then, each of these 
sites were mutated to encode for alanine, thus preventing phosphorylation and creating a protein 
that is constitutively dephosphorylated.  Two-dimensional gel analysis of wild-type E2F1 protein 
was performed, revealing two distinct spots for E2F1 on the gel.  Only the mutation of serine to 
alanine at the 375
th 
amino acid caused all E2F1 protein to migrate to only a single spot, 
representing the non-phosphorylated form of the protein
37
. Rb-E2F1 binding assays have also 
 
been performed but the results are conflicting.  One study, using in vitro assays, reported that 
E2F1 phosphorylation increased binding with Rb
37
. Another study using in vivo assays, however, 
reported that E2F1 phosphorylation decreased binding with Rb
38
. It seems, then, that E2F1 
phosphorylation somehow affects binding with Rb and thus affects cell cycle regulation. 
We wanted to take this same concept and apply it to E2F3.  The reasoning behind this was that 
E2F3 appears to have a more prominent role in proliferation than either E2F1 or E2F2. Sequence 
alignment between E2F1 and E2F3 was performed and the homologous 
phosphorlyation site on E2F3 (amino acid 390) was found (Figure 3.a).  This site was mutated to 
alanine, to mimic the non-phosphorylated form of E2F3, and was also mutated to aspartate to 
mimic phosphorylated E2F3.  As in previous studies with E2F1, these E2F3 mutants share identical 
migration patterns with wild type E2F3 (Figure 3.b), providing evidence that these mutations are 
behaving as the phosphorylated and non-phosphorylated versions of the protein. 
We introduced these same mutations in MEF’s and performed proliferation assays to 
analyze which form of the protein most promoted or inhibited proliferation.  MEF’s with E2F3+/+, 
E2F3
SA/SA
, and E2F3
SD/SD  
mutations were examined for relative levels of proliferation under 
normal gene expression conditions.  These results showed the highest level of proliferation for 
E2F3
SD/SD 
MEF’s, followed by E2F3SA/SA and then E2F3+/+.  However, another related 
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experiment, in which E2F3
SD/SD
, E2F3
SA/SA 
and E2F3
+/+ 
were overexpressed via a retrovirus in 
E2F3 knockout MEF’s showed different results.  In these MEF’s, retroviral expression of 
E2F3
+/+ 
generally showed the highest levels of proliferation in the MEF’s, followed by 
E2F3
SD/SD 
and then E2F3
SA/SA
. Therefore, it also seems possible that certain conditions in the 
wild type cell can promote very high levels of cellular growth. 
Figure 3. (Work and images by Hui Wang, Ph.D.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a.   Sequence alignment between E2F1 and E2F3 in mice and humans showing the 
homologous phosphorylation site that causes a conformational shift upon 
phosphorylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b.   Western blot of E2F3 mutants showing identical migration patterns to the two bands observed 
in wild type cells. Confirmation that this migration shift occurs due to phosphorylation was 
performed by phosphatase treatment, causing the disappearance of the upper, 
phosphorylated protein band. 
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Materials and Methods 
 
Creation of E2F3 mutant mice 
 
Site-directed mutagenesis was first performed in bacterial cell lines.  The mutation was 
made in exon seven of the E2F3 locus, creating a novel Sca1 restriction site for the S390A 
mutation and a novel BamH1 restriction site for the S390D mutation (Figure 4.a).  Cutting of the 
DNA with these restriction enzymes allowed for initial confirmation of the mutations.  DNA 
sequencing was also performed for confirmation (Figure 4.b). Embryonic stem cells (ES cells) 
were electroporated to transform the mutant DNA.  A neomycin marker, flanked by loxP sites 
and near the mutation site, was used to select for ES cells containing the integrated mutant DNA. 
The ES cells were transplanted into a mouse blastocyst, creating a chimeric mouse which was then 
bred and further crossed to cre transgenic mice to remove the neomycin cassette.  The initial 
presence and eventual removal of neomycin was confirmed by Southern blot and the genotypes 
confirmed by PCR (Figure 4.c).   The mice were then bred into an FVB background and 
intercrossed with Rb
-/+ 
mice to obtain the desired genotypes. 
Breeding strategy and harvesting of embryonic mice 
 
Rb
+/-
;E2F3
+/SA 
, Rb
+/-
;E2F3
+/SD
, Rb
+/-
;E2F3
SA/SA
, and Rb
+/-
;E2F3
SD/SD 
mice were crossed 
with other mice of identical genotype.  The mothers were observed every morning for the 
presence of a vaginal plug, indicating a recent mating.  This time point was considered E0.5 days.  
The embryos were harvested at the time points of E11.5 and E13.5 days.  Prior to harvesting, the 
mothers were injected with BrdU (100 ug/g of body weight) interperitoneally. Heartbeats for 
each embryo were observed under a microscope as an indicator of survival.  The embryos and 
their placentas were immediately fixed in formalin for histological analysis.  Yolk 
sacs were collected to genotype the embryos.  The placentas were stained with haematoxylin and 
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eosin to look for potential differences in cellular crowding in the placental labyrinth structures. 
 
PCR 
 
DNA was purified from tail samples or embryonic yolk sacs.  Standard PCR was used to 
amplify the desired fragments.  Primers used for E2F3 genotyping were as follows: 
AAAGCTCTTGGGAACTTCAG and GGGAGGACACAGATCACCAT.  Primers used for Rb 
genotyping were as follows: GAAGAACGAGATCAGCAG, 
ACAGGATGACTCACGGTACCTC, and CTGCTGGGATCAGTTAATGCTT. 
 
Figure 4. (Work and images by Hui Wang, Ph.D.) 
 
 
 
a.   Genetic scheme for creation and confirmation of desired 
mutations 
 
b. Sequencing of DNA from mutant 
mice to confirm genotype 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c. Confirmation by southern of pre-neomycin deletion genotypes (top left) and of mice genotypes 
after cre-induced neomycin deletion (top right). Confirmation by PCR for pre-neomycin deletion 
(bottom left) and for mice after cre-induced neomycin deletion (bottom right) 
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Harvest and tissue collection of adult mice 
 
Mice were bred to obtain Rb
+/-
;E2F3
SA/SA  
, Rb
+/-
;E2F3
+/+  
, and Rb
+/-
;E2F3
SD/SD 
genotypes.  
These mice were harvested at 11 months.  We harvested the pituitary, thyroid, lung, liver, kidneys, 
adrenal glands, pancreas, bladder, mammary glands, salivary glands, and femur. Pictures were 
taken of the pituitaries and of any other abnormalities noticed in the organs.  The tissues were 
immediately fixed in formalin.  Large tumors of the thyroid and pituitary were taken for both 
histology and for protein samples. 
Results 
 
Effect of E2F3 phosphorylation in Rb-mediated tumorigenesis 
 
Previous work was done on Rb
-/+
; E2F3
-/- 
mice in which deletion of E2F3, when 
 
compared to wild type, caused a decrease in pituitary tumors but an increase in medullary thyroid 
carcinomas, accompanied by metastases to other organs such as the lung and the liver
36
. In that 
study, E2F3 had zero functionality within the organism.  We wanted to assay whether the S390A or 
S390D mutation would have a significant effect on the protein’s functionality and thus mimic the 
knockout.  We used Rb
-/+
;E2F3
+/+ 
mice as a control and compared them to Rb
-/+
;E2F3
SA/SA
 
and Rb
-/+
;E2F3
SD/SD  
mice.  Previous studies showed that Rb
-/+ 
mice lived to approximately 10 
 
months of age.  We noted a slightly extended lifespan and thus harvested the mice at 11 months of 
age.  One result of this study was that Rb
-/+
;E2F3
SA/SA 
mice seemed to have a higher incidence of 
thyroid growths than either Rb
-/+
;E2F3
+/+ 
or Rb
-/+
;E2F3
SD/SD 
(Figure 5.a).  Within the Rb
-
 
/+
;E2F3
SA/SA 
genotype, female mice showed a significantly higher incidence of thyroid cancer 
 
than males compared to the other groups (Figure 5.b). 
 
Analysis of the pituitaries also showed an interesting trend.  Unfortunately histological 
analysis of the pituitaries was not possible and thus the following observations are based on 
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gross analysis of the pituitaries.  Tumor incidence seems relatively similar among Rb
-/+
;E2F3
+/+ 
, 
Rb
-/+
;E2F3
SA/SA 
and Rb
-/+
;E2F3
SD/SD  
mice (Figure 6.a and b).  However, tumor size appears to be 
greatest in the control mice. (Figure 6.c). 
Figure 5. 
 
 
a.   Rb-/+;E2F3SA/SA appear to have a higher incidence of thyroid growths than either Rb-/+;E2F3SD/SD or 
Rb-/+;E2F3+/+ 
 
 
b.   Rb-/+;E2F3SA/SA   female mice, but not male mice, show an increase in thyroid cancer compared to either 
Rb-/+;E2F3SD/SD or Rb-/+;E2F3+/+. This suggests a sex-dependent mechanism of tumorigenesis in the 
thyroid, which is also observed in human females. (* indicates a significant difference is present) 
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Figure 6 
 
 
 
a.   Graph showing no apparent differences in pituitary tumor incidence between any of the genetic groups. 
 
 
b.   Graph showing no apparent sex-dependent differences in pituitary tumor incidence between any of the 
genetic groups. 
 
Rb-/+;E2F3SA/SA Rb-/+;E2F3+/+ Rb-/+;E2F3SD/SD 
 
c. It was generally observed that pituitary size was surprisingly most severe in the Rb-/+;E2F3+/+ mice. 
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Effect of E2F3 phosphorylation on embryonic development in Rb-null mice 
 
It has been shown that embryos with both copies of Rb knocked out fail to develop 
normally.  These embryos show ectopic apoptosis and proliferation in the central and peripheral 
nervous system, in the placenta, and in other organs.  Furthermore, erythroid, neuronal, and 
skeletal muscles cells do not terminally differentiate
15,39,40
. It is thought that a combination of 
erythroid abnormalities and placental abnormalities cause fetal death by the embryonic age of 
13.5 days.  Previous studies have shown that by knocking out E2F3 in these Rb-null embryos, 
some of these defects are alleviated, such as an increase in proper enucleation of red blood 
cells
35
. Furthermore, the lifespan of these embryos increases, although they still do not survive 
to term due to the severity of the Rb-null phenotype.  We first observed embryos at E13.5.  In the 
 
control group, Rb
-/-
;E2F3
+/+ 
mice, only 2/17 (~12%) mice were found alive.  2/15 (~13%)  Rb
-/-
 
 
;E2F3
+/SD 
mice and 0/6 (0%) of Rb
-/-
;E2F3
SD/SD 
were found alive at this point (Figure 8).  The 
survival for embryos with the S390A mutation was slightly higher, although not by a significant 
amount.  3/13 (23%) of the Rb
-/-
;E2F3
+/SA 
mice and 1/6 (17%) of the Rb
-/-
;E2F3
SA/SA 
mice were 
found alive at this point.  It seems, then, that the Rb mutation is dominant by this point in 
development and these mice are dying regardless of the state of E2F3.  We then observed the 
embryos at E11.5 and noticed a trend that was not seen before.  In the control group, Rb
-/-
 
;E2F3
+/+
, 5/6 (83%) of the embryos were still alive at this age (Figure 7).  0/3 (0%)  Rb
-/-
 
 
;E2F3
+/SD 
mice and 2/11 (18%) of Rb
-/-
;E2F3
SD/SD 
were found alive at this point.  Interestingly, 
the survival for S390A embryos was much higher than S390D embryos at this point.  3/5 (60%) 
Rb
-/-
;E2F3
+/SA 
mice and 8/11 (73%) of Rb
-/-
;E2F3
SA/SA 
were found. 
Previous studies also show that one of the primary causes of embryonic lethality due to a 
lack of Rb is overproliferation in the trophoblast of the placenta
16
. This limits nutrient transport 
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between the mother and fetus and eventually causes death.  Comparison of the hematoxylin and 
eosin stained placentas produced observations which correlated with the experimental findings. 
The placentas from E11.5 Rb
-/-
;E2F3
SD/SD 
embryos had fewer maternal blood spaces and an 
overall greater degree of cellular crowding than either Rb
-/-
;E2F3
SA/SA 
or Rb
-/-
;E2F3
+/+ 
(Figure 
 
9).  This points to a similar mechanism presented in previous work where the E2F3 induced 
proliferation was the primary cause of death.  Ablation of E2F3 function in the cell increased the 
lifespan of these organisms, just as may have occurred in this experiment. 
 
 
 
Figure 7. 
 
 
a.   At E11.5 the vast majority of Rb-/-;E2F3SD/SD and Rb-/-;E2F3SD/+ mice were dead. However, Rb- 
null embryos with wild-type E2F3 or the SA mutation in any number of copies did not vary 
significantly and were primarily alive at this time point. (* indicates a significant difference is 
present) 
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Format: # Alive(#Dead) 
 
SD E11.5           
 Rb
+/+
; 
E2F3
+/+ 
Rb
+/+
; 
E2F3
+/SD 
Rb
+/+
; 
E2F3
SD/SD 
Rb
+/-
; 
E2F3
+/+ 
Rb
+/-
; 
E2F3
+/SD 
Rb
+/-
; 
E2F3
SD/SD 
Rb
-/-
; 
E2F3
+/+ 
Rb
-/-
; 
E2F3
+/SD 
Rb
-/-
 
;E2F3
SD/SD 
 
Total 
Avg litter 
ize 
Observed 1(1) 1(0) 12(1) 3(0) 5(2) 20(3) 2(0) 0(3) 2(9) 46(19) 9.29 pups 
Expected 2 3 12 3 6 23 2 3 12 66  
 
 
 
SA E11.5           
 Rb
+/+
; 
E2F3
+/+ 
Rb
+/+
; 
E2F3
+/SA 
Rb
+/+
; 
E2F3
SA/SA 
Rb
+/-
; 
E2F3
+/+ 
Rb
+/-
; 
E2F3
+/SA 
Rb
+/-
; 
E2F3
SA/SA 
Rb
-/-
; 
E2F3
+/+ 
Rb
-/-
; 
E2F3
+/SA 
Rb
-/-
 
;E2F3
SA/SA 
 
Total 
Avg litter 
size 
Observed 4(0) 2(0) 6(1) 10(0) 10(3) 16(2) 3(1) 3(2) 8(3) 62(12) 9.25 pups 
Expected 3 6 10 6 12 20 3 6 10 74  
 
b.   Table showing the exact values obtained for the survival of embryos at E11.5.  Also shows the expected mendelian ratios 
from the crosses performed. 
 
 
 
 
 
c. Pictures of typical embryos at E11.5. Death of embryos noted primarily by presence or absence of 
heartbeat.  Pale color and hemorrhaging also acted as additional indicators of embryonic death. 
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Figure 8. 
 
 
 
a.   At E13.5 the vast majority of all Rb-null mice were dead. The lack of Rb had become the 
dominating phenotype and appears to be masking any phenotypes we might have observed 
from E2F3. (* indicates a significant difference is present) 
 
 
Format: # Alive(#Dead) 
 
SD E13.5           
 Rb
+/+
; 
E2F3
+/+ 
Rb
+/+
; 
E2F3
+/SD 
Rb
+/+
; 
E2F3
SD/SD 
Rb
+/-
; 
E2F3
+/+ 
Rb
+/-
; 
E2F3
+/SD 
Rb
+/-
; 
E2F3
SD/SD 
Rb
-/-
; 
E2F3
+/+ 
Rb
-/-
; 
E2F3
+/SD 
Rb
-/-
; 
E2F3
SD/SD 
 
Total 
Avg litter 
size 
Observed 9(0) 20(2) 9(0) 12(0) 36(11) 25(0) 2(11) 2(13) 0(6) 115(43) 9.29 pups 
Expected 10 20 10 20 39 20 10 20 10 159  
 
SA E13.5           
 Rb
+/+
; 
E2F3
+/+ 
Rb
+/+
; 
E2F3
+/SA 
Rb
+/+
; 
E2F3
SA/SA 
Rb
+/-
; 
E2F3
+/+ 
Rb
+/-
; 
E2F3
+/SA 
Rb
+/-
; 
E2F3
SA/SA 
Rb
-/-
; 
E2F3
+/+ 
Rb
-/-
; 
E2F3
+/SA 
Rb
-/-
; 
E2F3
SA/SA 
 
Total 
Avg litter 
size 
Observed 6(0) 14(1) 3(0) 12(2) 28(1) 18(1) 0(4) 3(10) 1(5) 85(24) 8.38 pups 
Expected 7 14 7 14 27 14 7 14 7 111  
 
 
b.   Table showing the exact values obtained for the survival of embryos at E11.5.  Also shows the 
expected mendelian ratios from the crosses performed. 
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c. Pictures of typical embryos at E13.5. Death of embryos noted primarily by presence or absence of 
heartbeat.  Pale color and hemorrhaging also acted as additional indicators of embryonic death.  Both 
higher mortality and a greater degree of reabsorption were noted at E13.5 compared to E11.5 
 
 
 
 
Figure 8. 
 
 
 
Rb-/+;E2F3SA/SA Rb-/+;E2F3+/+ Rb-/+;E2F3SD/SD 
 
 
 
H&E staining of E11.5 placentas showing a greater degree of cellular crowding in the labyrinth of Rb-/-;E2F3SD/SD+ placentas 
(right) that is potentially causing earlier lethality due to lack of correct nutrient transport between mother and pup. 
 18 
Discussion 
 
This study sought to analyze the effects of E2F3 phosphorylation in vivo in the absence 
 
or partial absence of the Rb gene.  Previous work demonstrated a role for E2F3 in both 
tumorigenesis as well as embryonic development. That work, however, was only performed by 
knocking E2F3 out of the organisms.  Phosphorylation, conversely, is a more biologically relevant 
and common change found to affect the way that proteins function and interact with each other.  
With this is mind, we hoped to understand how this phosphorylation affects E2F3’s activity in the 
cell and in the context of cancer.  Ultimately, we hope to understand this mechanism in order to 
create novel chemotherapies for cancers propagated in this manner. 
To reiterate, one main finding of this study so far is that the E2F3
S390A 
mutation (non- 
 
phosphorylation mimicking) appears to cause an increase in thyroid tumor incidence, primarily 
in females.  Interestingly, both E2F3
S390A 
and E2F3
S390D 
appear to decrease average pituitary 
tumor size, although this data has not been quantified.  Another finding is that the Rb
-/-
 
;E2F3
S390D 
mutation causes earlier embryonic lethality than either Rb
-/-
;E2F3
+/+ 
or Rb
-/-
 
 
;E2F3
S390A
. 
 
The reasons behind these trends are still unclear, although a few models have been 
suggested.  E2F1 and E2F3 are known to share similar functions.  Phosphorylation has not been 
well studied in E2F3; however, there have been a number of studies of phosphorlyation at various 
sites in E2F1.  It is likely that E2F1 and E2F3 function in a somewhat similar manner. Evidence 
for this comes from their seemingly overlapping abilities to support proliferation as well as 
development when either of the E2F’s is knocked out.  One general mode of action that has been 
suggested is as follows: when Rb is phosphorylated, it releases E2F1 which proceeds to bind to its 
target DNA.  This binding activates the transcription of genes, including 
 19 
genes necessary for replication, which code for cyclins, cdk’s, and other necessary proteins. 
 
Two of these targets, which are also a targets of E2F3, are cyclin A and cdk2.  The E2F1 protein 
contains a binding site for cyclin A which then allows the attached cdk2 to associate with and 
phosphorylate E2F1 (as well its heterodimeric partner DP-1) at serine 375.  This phosphorylation 
has been found to weaken E2F1’s binding to DNA, as well as strengthen its binding to Rb37. 
This then acts as a negative feedback loop, ensuring that E2F’s do not promote active 
 
transcription of replication-inducing genes for too long.  Applying this same model to the results 
obtained gives somewhat mixed results.  This could help to explain why thyroid tumor incidence is 
more prevalent in the E2F3
S390A 
mice, but doesn’t help to explain the gender bias observed. 
Furthermore, it does not explain why mice wild-type for E2F3 show more severe pituitary 
tumors or why embryonic lethality would occur earlier for E2F3
S390D 
mice.  E2F1 and E2F3, 
 
while very similar, still have differences both in terms of protein structure and expression 
patterns.  Perhaps, then, phosphorylation does not affect Rb-binding affinity similarly between 
these two proteins.  It’s possible that phosphorylated E2F3 binds more tightly to DNA and is 
thus why proliferation occurs more rapidly in these cells.  This would explain the presence of 
phosphorylated E2F3 in mammary tumor cell lines, as well as the increased levels of 
proliferation noted in the E2F3
S390D 
MEF’s.  This mode of operation, however, then contradicts 
 
the results found in the pituitary and suggests that a more complex level of regulation and 
activity is present. 
Previous work has shown that E2F1-3 can behave as activators under some conditions, but 
repressors under others
42
. This brings to light the possibility that such differences could also be 
present in a tissue-specific manner.  It is possible that the phosphorylated forms of E2F3 
could be behaving as activators in one scenario, and repressors in another, giving the somewhat 
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conflicting phenotypes observed in this study.  Other complexities could arise from the fact that 
E2F3 is known to signal for apoptosis in over-proliferating cells
35
. Apoptosis signaling is another 
biochemical pathway known to vary from tissue to tissue, and could be one reason why tumor 
spectrums vary across the genotypes.  Yet another source of complexity comes from differential 
activation of tissue-specific genes depending on which E2F is present.  For example, PTTG-1, 
which is primarily activated by E2F1, is a gene that when overexpressed leads to cancer of the 
pituitary, thyroid, and other endocrine glands, with other tissues being unaffected
41
. This is merely 
one example but shows that tissue specific gene induction also plays a role in tumorigenesis in an 
E2F dependent manner. 
For future experiments we would like to analyze proliferation as well as apoptosis in the 
pituitary and thyroid.  Furthermore, in Rb
-/+
;E2F3
-/- 
experiments, mice showed an increase in 
metastases from the thyroid to the lung, liver, and other organs.  We wish to quantify the level of 
c-cell invasion in these tissues to ascertain whether a similar trend exists with phosphorylation. We 
would also like to look into phosphorylation-specific effects on Rb-E2F3 binding.  The strength 
with which each of these mutant E2F3’s binds to Rb could give us insight into how 
E2F3 and Rb are interacting in vivo and whether this behavior is similar to or different than 
E2F1.  Hopefully by understanding E2F3’s behavior in vivo we will eventually be able to 
regulate it to help prevent a large variety of cancers. 
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